Skip to main content

Ana Barreira Diaz

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Ana Barreira Diaz

Institutions of which they are part

Liver Diseases
Vall Hebron Institut de Recerca

Projects

Impact of HLA haplotypes and HDV viremia in developing of clinical events and quality of life of patients with chronic hepatitis delta.

IP: Maria Buti Ferret
Collaborators: Maria Jose Herrero Mata, Ana Barreira Diaz, Maria del Mar Riveiro Barciela, Jordi Llaneras Artigues, Adriana Palom Agusti, Maria luisa Roade Tato
Funding agency: Instituto de Salud Carlos III
Funding: 117370
Reference: PI20/01692
Duration: 01/01/2021 - 30/06/2025

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Julia Salvador Lodosa

Julia Salvador Lodosa

Read more
Ernest Hidalgo Llompart

Ernest Hidalgo Llompart

Main researcher
Hepato-bilio-pancreatic surgery (HBP) and liver transplantation
Read more
Inmaculada Jimenez Ariza

Inmaculada Jimenez Ariza

Administrative
Accounting and Revenue Unit
Finances Area
Read more
Laura Gonzalez Garcia

Laura Gonzalez Garcia

Growth and Development
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.